CellMax Life possesses technologies for molecular diagnosis and circulating tumor cell (CTC) blood test. Its CMx® diagnostic platform breaks through the boundaries of traditional CTC technology. By using the proprietary biomimetic membrane-coated microfluidic chip, the CTCs captured from the blood can be maximized. Tumor cells can be detected from up to 109 blood cells/ml, increasing the accuracy of tumor detection. The CMx® platform combines DNA and CTC analysis using the exclusive SMSEQ® (single-molecule-sequencing) platform to more accurately decode tumor genes through ctDNA, making CellMax Life's liquid biopsy the first and only blood test to be recommended in the National Comprehensive Cancer Network (NCCN) guideline.
Recently, CellMax's R&D team has been actively developing an automated in vitro diagnostic system (IVD), while its products and services team focuses on early cancer screening and personalized targeted cancer therapy and diagnostics.
Early Detection of Cancer – Research Results in Colorectal Cancer and Prostate Cancer Capture Attention
This year, CellMax Life presented its research findings in early colorectal cancer screening at the Precision Medicine World Conference (PMWC). In 620 subjects, the sensitivity of the screening can reach 84 to 88%, and the specificity of 97% is higher than that of its current competitor Cologuard. The early prostate cancer research presented at 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) is even more significant. The study included 200 PSA gray zone patients. For these patients, CellMax Life's screening had an 80% sensitivity and over 90% specificity for early prostate cancers. The research can help reduce the number of unnecessary prostate biopsies in the clinical setting. These two types of early cancer screening provide new methods with better sensitivity and specificity provided at significantly lower costs. The release of other cancer-related products in the future could revolutionize the field.
Personalized Targeted Cancer Therapy – Helping Patients with Solid Tumors Precisely Select Therapy
CellMax Life has had a breakthrough this year in the assessment and monitoring of the immunotherapy eligibility of patients with solid tumors. Analysis of the PD-L1 protein expression on the CTCs can be used as a basis for precision targeted therapy and evaluation of drug efficacy. The results showed that the sensitivity of screening early-stage lung cancer with PD-L1 is as high as 90%. For patients with advanced lung cancer, about 50% tested positive for PD-L1 and the sensitivity is consistent with the clinical study. The test can help doctors to select drugs precisely in the future. For patients with solid tumors for whom tissue biopsies are difficult to obtain, the test may be the best solution outside of tissue testing, helping late-stage patients choose immunotherapy and targeted therapy drugs. The research was presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
At this year's Taiwan Healthcare+ Expo, CellMax Life will focus on boosting its promotion and collaboration with hospitals in personalized targeted therapy and diagnostics products. In addition, CellMax Life will expand its early-stage cancer diagnostics business in New Zealand, Australia, South East Asia, North Asia, and regional markets in the Middle East by cooperating with local distributors.
||Product and Service
|Early detection and Screening of cancer
- DNA genetic risk test
- CRC protect™
- Prostate protect™
|Personalized Targeted Therapy Selection
- Liquid biopsy
- CTC-based PD-L1 assay
- CRC monitor™
- Prostate monitor™
(Editing by Jim Shih, Research Center for Biotechnology and Medicine Policy)